Literature DB >> 7791161

Classification criteria for polymyositis and dermatomyositis.

K Tanimoto1, K Nakano, S Kano, S Mori, H Ueki, H Nishitani, T Sato, T Kiuchi, Y Ohashi.   

Abstract

OBJECTIVE: The establishment of classification criteria for polymyositis (PM) and dermatomyositis (DM).
METHODS: Questionnaires inquiring about patients with DM, PM, systemic lupus erythematosus, progressive systemic sclerosis and noninflammatory neuromuscular diseases were distributed to the main medical institutes in Japan. Data were collected and analyzed by computer.
RESULTS: Among skin lesions of DM, heliotrope rash, Gottron's sign and erythema or purpura on the extensor surfaces of the extremity joints were shown to be distinguishing criteria. In both DM and PM, proximal muscle weakness, muscle grasping and spontaneous pain, nondestructive arthritis or arthralgia, elevated CK or aldolase level, presence of systemic inflammatory signs, myogenic changes on EMG, positive and anti Jo-1 antibody and pathologic findings compatible with inflammatory myositis were distinguishing criteria items.
CONCLUSION: When a patient satisfies one of 3 skin lesion items and at least 4 other items, he or she shall be classified as having DM, sensitivity 94.1%. When a patient satisfies at least 4 items other than skin lesion items, he or she shall be classified as having PM, sensitivity 98.9%. Specificity of DM and PM is 95.2%.

Entities:  

Mesh:

Year:  1995        PMID: 7791161

Source DB:  PubMed          Journal:  J Rheumatol        ISSN: 0315-162X            Impact factor:   4.666


  57 in total

1.  Technical and clinical evaluation of anti-ribosomal P protein immunoassays.

Authors:  M Mahler; K Kessenbrock; J Raats; M J Fritzler
Journal:  J Clin Lab Anal       Date:  2004       Impact factor: 2.352

2.  Association of systemic and thyroid autoimmune diseases.

Authors:  Edit Biró; Zoltán Szekanecz; László Czirják; Katalin Dankó; Emese Kiss; Nóra Anna Szabó; Gabriella Szucs; Margit Zeher; Edit Bodolay; Gyula Szegedi; Gyula Bakó
Journal:  Clin Rheumatol       Date:  2005-10-25       Impact factor: 2.980

Review 3.  Classification of myositis.

Authors:  Ingrid E Lundberg; Marianne de Visser; Victoria P Werth
Journal:  Nat Rev Rheumatol       Date:  2018-04-12       Impact factor: 20.543

Review 4.  Effects of corticosteroids and immunosuppressors on idiopathic inflammatory myopathy related myocarditis evaluated by magnetic resonance imaging.

Authors:  Y Allanore; O Vignaux; L Arnaud; X Puéchal; S Pavy; D Duboc; P Legmann; A Kahan
Journal:  Ann Rheum Dis       Date:  2006-02       Impact factor: 19.103

5.  Mortality and prognostic factors in idiopathic inflammatory myositis: a retrospective analysis of a large multicenter cohort of Spain.

Authors:  Laura Nuño-Nuño; Beatriz Esther Joven; Patricia E Carreira; Valentina Maldonado-Romero; Carmen Larena-Grijalba; Irene Llorente Cubas; Eva Gloria Tomero; María Carmen Barbadillo-Mateos; Paloma García De la Peña Lefebvre; Lucía Ruiz-Gutiérrez; Juan Carlos López-Robledillo; Henry Moruno-Cruz; Ana Pérez; Tatiana Cobo-Ibáñez; Raquel Almodóvar González; Leticia Lojo; María Jesús García De Yébenes; Francisco Javier López-Longo
Journal:  Rheumatol Int       Date:  2017-09-02       Impact factor: 2.631

Review 6.  The evolving spectrum of polymyositis and dermatomyositis--moving towards clinicoserological syndromes: a critical review.

Authors:  Sarah Tansley; Harsha Gunawardena
Journal:  Clin Rev Allergy Immunol       Date:  2014-12       Impact factor: 8.667

7.  Myositis-specific and myositis-associated autoantibodies in Indian patients with inflammatory myositis.

Authors:  Puja Srivastava; Sanjay Dwivedi; Ramnath Misra
Journal:  Rheumatol Int       Date:  2016-05-14       Impact factor: 2.631

8.  Diagnostic and prognostic values of anti glucose-6-phosphate isomerase antibodies in community-recruited patients with very early arthritis.

Authors:  F Jouen; O Vittecoq; F Leguillou; I Tabti-Titon; J F Menard; O Mejjad; S Pouplin; P Boumier; P Fardellone; A Gayet; D Gilbert; F Tron; X Le Loët
Journal:  Clin Exp Immunol       Date:  2004-09       Impact factor: 4.330

9.  Dermatomyositis associated with HIV-1 infection in a Nigerian adult female: a case report.

Authors:  D Ogoina; A Umar; O R Obiako
Journal:  Afr Health Sci       Date:  2012-03       Impact factor: 0.927

10.  Increased plasma amyloid-beta42 protein in sporadic inclusion body myositis.

Authors:  Wilson F Abdo; Tom van Mierlo; Gerald J Hengstman; H Jurgen Schelhaas; Baziel G van Engelen; Marcel M Verbeek
Journal:  Acta Neuropathol       Date:  2009-06-06       Impact factor: 17.088

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.